

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity : Neuren Pharmaceuticals Limited
ABN : 111 496 130

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Robin Lance Congreve
Date of last notice	9 February 2005

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect interests
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none"> 1. T.A.C. Murray and Quartet Equities Limited as trustees of The Congreve Family Trust and the relevant interest is as a beneficiary of The Congreve Family Trust 2. EndocrinZ Founders Limited and the relevant interest is as a director and shareholder 3. Oceania & Eastern Biotech Limited and the relevant interest is as a director and indirect shareholding held by associated interests 4. Hazardous Investments Limited and the relevant interest is as a director and indirect shareholding held by associated interests 5. NeuronZ Limited and the relevant interest was as a director
Date of change	<ul style="list-style-type: none"> • Resigned as director of NeuronZ 21 Feb 2006 • Shares acquired through rights issue 1 Feb 2008
No. of securities held prior to change	23,646,115
Class	Ordinary Shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	<ul style="list-style-type: none"> • 1,852,122 by T.A.C. Murray and Quartet Equities Limited as trustees of The Congreve Family Trust under the rights issue • 3,129,713 by Oceania & Eastern Biotech Limited under the rights issue • 1,646,855 by Hazardous Investments Limited under the rights issue
Number disposed	Indirectly 12,345,898 through resignation as director of NeuronZ
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<ul style="list-style-type: none"> • NZ\$0.16 per share under the rights issue • Nil on resignation as director
No. of securities held after change	17,928,907 Ordinary Shares and 1,528,892 unlisted options to acquire Ordinary Shares at NZ\$0.392 each until March 2009
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ul style="list-style-type: none"> • Rights issue participation • Resignation as director

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	NIL
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.